Yasmeen Farra1, Dongyang Yi1, James Coleman2, Praveen Kulkarni2,3, Craig Ferris2,3, Jessica Oakes1, and Chiara Bellini1
1Bioengineering, Northeastern University, Boston, MA, United States, 2Center for Translational Neuroimaging, Northeastern University, Boston, MA, United States, 3Psychology, Northeastern University, Boston, MA, United States
Synopsis
Cannabis
use is rising worldwide. Robust standardized methodologies in animal models are
needed to further elucidate the impact of cannabis on overall health. Our aim
was to identify acute exposure methods that provide a viable model for human cannabis
consumption. C57BL/6J mice were exposed to cannabis aerosols using a Volcano® vaporizing device. Cannabis dosage levels were
identified that elicited a human-like response.
Animals were exposed while undergoing fMRI scans of their neurological activity.
BOLD data, coupled with blood pressure and behavioral tests, demonstrated that
our exposure methods generated a reproducible response that can be adapted for
further studies.
Introduction
Cannabis
is used by an estimated 183 million adults annually, representing well over
half of all illicit drug use worldwide.1 There is inconclusive
scientific evidence regarding the health effects of cannabis and therefore
there is a need for established, reproducible methods of acute cannabis
exposure in animal studies that model human consumption.2-7 Only
then can these methods be expanded to develop a comprehensive understanding of
the long-term, systematic effects of cannabis. In this work, we modeled the
health effects of acute cannabis administration in recreational-use populations
using nose-only, cannabis aerosol inhalation in mice. Methods
Male C57BL/6J mice aged 8-10 weeks and weighing
approximately 23-27 grams were used. Two sets of experiments were performed:
(1) correlation between cannabis exposure and THC concentration in the blood (n
= 18) and (2) assessment of neurological, physiological, and behavioral changes
in mice following exposure (n = 24) to an optimal amount of cannabis. For both objectives, acute nose-only cannabis
exposure was compared with nose-only exposure to room air. Cannabis containing 13.1% THC and negligible CBD was used
in all procedures. The Volcano® vaporizing system (Storz
and Bickel, Tuttlingen, Germany) was used to fill a bag with cannabis aerosols.8-9 Particles
generated from cannabis were examined for particle mass concentration and
sizing. An ELISA assay for serum THC concentration identified the optimal
cannabis dosage to match observed human response. Assessment of
neurological activity in response to cannabis exposure was conducted using
functional magnetic resonance imaging (fMRI). An inline duct fan was
modified to pump cannabis directly to an awake restrained mouse via nose-only
tubing (Fig. 1). Imaging took
place using a Bruker BioSpec 7.0T/20-cm USR horizontal magnet (Bruker,
Billerica, Massachusetts) and a 20-G/cm magnetic field gradient insert
(ID=12cm). Functional images were acquired using a single-shot RARE (Rapidly
Acquired with Refocused Echos) pulse sequence (18 slices; 0.75 mm; FOV 1.8 cm;
data matrix 96 X 96; TR 6 sec; TE 4 msec; Effect ET 24 msec; 15 min acquisition
time). Images were aligned and registered to a 3D mouse atlas, which is
segmented and labeled with 116 discrete anatomical regions. Matrices that
transformed each subject’s anatomy were used to embed each slice within the atlas.
Images acquired after cannabis exposure were compared to baseline. A
non-parametric Kruskal-Wallis test was used to compare the average signal
intensity in each of the 15,000 voxels for their first 5 minutes baseline
(acquisitions 1-50) to minutes 5 – 15 (acquisitions 50-150). Mice were also tested for physiological and behavioral
responses to cannabis exposure using non-invasive blood pressure
tail-cuffs and open field behavioral tests. Statistical analyses of all
data were performed using a threshold for statistical significance of p <
0.05. Results
Particulate
matter quantification showed that the exposure system varies linearly in dose
efficiency with amount of cannabis input. A THC serum concentration of
approximately 136 ng/mL was produced, which is comparable with reported values
of human THC concentration following high-dose cannabis consumption. THC
concentrations present in blood samples following acute inhalation experienced a
linear effect with cannabis dosages (Fig. 2). fMRI imaging
demonstrated that cannabis caused increased BOLD activation in many
regions of the brain (Fig. 3). Blood pressure and heart rate were shown to
decrease following acute cannabis exposure. Open-field behavioral
tests indicated that despite similar levels of overall mobility,
cannabis-exposed mice spent significantly more time near walls and away from
the center of the testing space than the mice exposed only to room air (Fig. 4). Discussion
The
methods conducted in this work produce a consistent effect in mice exposed to
aerosolized cannabis. We show that the cannabis particles generated by the
Volcano® system are within the respirable range and cause a
physiological response within the body (Fig. 5). Clear CNS-mediated effects of
cannabis inhalation, are exhibited by fMRI results of significant positive BOLD
signal activation in 15 brain regions and negative BOLD activation in 25
regions of the brain, including the brain stem which modulates sympathetic and
parasympathetic response. Blood pressure and heart rate results also indicate
that there is a bradycardic and hypotensive reaction that agrees with the
effects shown in the fMRI data. Finally, behavioral testing data suggests that
cannabis-exposed mice experienced significant levels of anxiety following
exposure, which agrees with the common human symptoms of anxiety and psychosis
following consumption of cannabis.10Conclusion
Acute
cannabis exposures in mice were shown to provide a viable model for human
cannabis consumption. Particles delivered via nose-only inhalation elicited
physiological, neurological and behavioral responses in the mice as supported
by the fMRI data, blood pressure, and behavioral activity tests.Acknowledgements
This work was supported, in part, by the Northeastern University Tier 1 Seed Funds. Undergraduates Andrew Szendrey and Chris Le are gratefully acknowledged for their assistance in the experimental methods expressed here. References
- UNDOC. (2017). Fact Sheet on Statistics and Trends in
Illicit Drugs. World Drug Report. https://doi.org/10.18356/c595e10f-en
- Fergusson, D. M., & Boden, J. M. (2008). Cannabis
use and later life outcomes. Addiction, 103(6).
https://doi.org/10.1111/j.1360-0443.2008.02221.x
- Baker, D., Pryce, G., Giovannoni, G., & Thompson,
A. J. (2003). Review The therapeutic potential of cannabis. Lancet Neurology,
2(May), 291–298. https://doi.org/10.1016/S1474-4422(03)00381-8
- Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio,
M., Duffy, S., Hernandez, A. V., … Kleijnen, J. (2015). Cannabinoids for
medical use: A systematic review and meta-analysis. JAMA - Journal of the
American Medical Association, 313(24), 2456–2473.
https://doi.org/10.1001/jama.2015.6358
- Woolridge, E., Barton, S., Samuel, J., Osorio, J.,
Dougherty, A., & Holdcroft, A. (2005). Cannabis use in HIV for pain and
other medical symptoms. Journal of Pain, 29(4).
https://doi.org/10.1016/j.jpainsymman.2004.07.011
- Hall, W., & Degenhardt, L. (2009). Adverse health
effects of non-medical cannabis use. Lancet, 374(9698),
1383–1391. https://doi.org/10.1016/S0140-6736(09)61037-0
- Patton, G. C., Coffey, C., Carlin, J. B., Degenhardt,
L., Lynskey, M., & Hall, W. (2002). Cannabis use and mental health in young
people: cohort study. BMJ, 325(7374).
https://doi.org/10.1136/bmj.325.7374.1195
- Hazekamp, A., Ruhaak, R., Zuurman, L., Van Gerven, J.,
& Verpoorte, R. (2005). Evaluation of a Vaporizing Device (Volcano1) for
the Pulmonary Administration of Tetrahydrocannabinol. International Journal
of Drug Development and Research, 3(2), 26–33.
https://doi.org/10.1002/jps
- Abrams, D. I., Vizoso, H. P., Shade, S. B., Jay, C.,
Kelly, M. E., & Benowitz, N. L. (2007). Vaporization as a smokeless
cannabis delivery system: A pilot study. Clinical Pharmacology and
Therapeutics, 82(5), 572–578. https://doi.org/10.1038/sj.clpt.6100200
- Morrison, P. D., Zois, V., McKeown, D. A., Lee, T. D.,
Holt, D. W., Powell, J. F., … Murray, R. M. (2009). The acute effects of
synthetic intravenous9- tetrahydrocannabinol on psychosis, mood and cognitive
functioning. Psychological Medicine, 39(10), 1607–1616. https://doi.org/10.1017/S0033291709005522